Search results
Results from the WOW.Com Content Network
On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid ...
On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without ...
(Reuters) - Vir Biotechnology's shares plunged 45% to a more than three-year low on Thursday after the company's experimental antibody therapy to prevent a type of flu failed to meet its goals in ...
On Wednesday, Vir Biotechnology Inc (NASDAQ:VIR) announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart and elebsiran for chronic hepatitis ...
On Dec. 7, GlaxoSmithKline (Glaxo) and Vir Biotechnology announced an update to preclinical data concerning bioRxiv1, a preprint server, demonstrating that sotrovimab, an investigational monoclonal...
George A. Scangos was a pharmaceutical executive and former chief executive officer of Vir Biotechnology from 2017 to 2023. Scangos was previously the chief executive officer of Biogen from 2010 to 2016 and of Exelixis from 1996 to 2010. [1] [2] Prior to joining industry, Scangos was a professor of biology at Johns Hopkins University.
Sotrovimab's development began in December 2019, at Vir Biotechnology when Vir scientists first learned of the initial COVID-19 outbreak in China. [18] Vir subsidiary Humabs BioMed had already compiled a library of frozen blood samples from patients infected with viral diseases, including two samples from patients infected with SARS-CoV-1. [18]
Vir Biotechnology Inc (NASDAQ: VIR) announced new data from its hepatitis B virus (HBV) portfolio aimed at achieving a functional cure. New preliminary data from an ongoing Phase 2 trial ...